XML 57 R47.htm IDEA: XBRL DOCUMENT
v3.23.2

ALLIANCES - Additional Information (Details) - BridgeBio $ in Millions | 3 Months Ended
--- | ---
Jun. 30, 2022 USD ($)
Alliance Statement [Line Items] |
Upfront payments made to collaborative partner | $ 90
Consideration for contingent development and regulatory approval | $ 815

X
- Definition This element represents that additional aggregate consideration for contingent development and regulatory approval milestone payments. + References No definition available. + Details
Name: | bmy_ConsiderationForContingentDevelopmentAndRegulatoryApproval
Namespace Prefix: | bmy_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Upfront payments made to partner as part of collaborative arrangement. + References No definition available. + Details
Name: | bmy_UpfrontPaymentsMadeToCollaborativePartner
Namespace Prefix: | bmy_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | bmy_AlliancesAndCollaborationCompaniesAxis=bmy_BridgeBioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |